ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD24/Anti-CD3 Bispecific Antibody ONC-783

Its studies are led by OncoC4.

Furthest: phase 1, since Feb 6, 20261 company-led study, 1 open or runningNext primary completion: Aug 1, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
OncoC411 open or runningphase 1since Feb 6, 2026Feb 6, 2026Aug 1, 2027phase 1 · NCT07408258

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 6, 2026First study: phase 1 study in Advanced Solid TumorFirst studyNCT07408258 · 20 planned · United States

Ahead

  1. Aug 1, 2027Primary completion: phase 1 study in Advanced Solid TumorNCT07408258

TargetBeta

CD24 →CD3E →read by rule
“A humanized bispecific T-cell engaging antibody directed against both the cell surface antigen cluster of differentiation 24 (CD24) and the human T-cell surface antigen CD3, ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07408258Advanced Solid Tumor · United States1RecruitingAug 1, 202720

How it is read

Names in the registry

  • “ONC-783”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.